The expansion of the auto injector market has been triggered by the need for improvements in quality of life (QOL) and patient compliance.
From human factors and usability studies to new injection technologies and breakthrough manufacturing processes, the ultimate goal of an auto injector device is to enhance the injection experience while ensuring the desired drug is delivered safely and effectively.
However, to realise an auto injector from concept to mass production requires designs that are both innovative and practical, an intricate manufacturing processes, a clear understanding of regulatory submission requirements, trusted partners and more.
SHL has made it a tradition to attend the annual PDA Universe of Prefilled Syringes and Injection Devices conference where key SHL staff connect with experts from various fields and customers. At this event SHL will introduce some of its newest technologies and innovative devices to the audience of biopharmaceutical players and related consultants.
In addition, usability tools and needleless trainers will available for demonstration which will help to assist patients in becoming more familiar with their devices.
Commenting on this year’s upcoming event, executive VP of SHL Medical USA and president of SHL Pharma Lucio Giambattista stated: "Over the years we looked into developing the right technologies that will enhance the patient experience and also to address unmet needs in the industry.
"With the success of our auto injectors like the DAI, then Mollyand now Amber, we believe we are on track, but we also have a lot more in the pipeline. At this PDA we not only be exhibiting and sending a large delegation of staff from our various offices, but also arranging for a number of private innovation meetings where we showing some of the newest devices and working prototypes."
SHL will be exhibiting at Booth# 411, where SHL’s latest auto injectors, such as Amber, will be available for demonstration to biopharmaceutical companies attending.